Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29968774 | 0.97 | CA12 (0.62) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL28233992 | 0.92 | SMN1; SMN2 (0.67) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL23592712 | 0.90 | SMN1; SMN2 (0.58) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL5473926 | 0.83 | — | — | |
| SCHEMBL4724826 | 0.79 | CA12 (1.00) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL4141702 | 0.77 | — | — | |
| SCHEMBL11688163 | 0.77 | CA1 (0.69) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL222875 | 0.77 | CA12 (0.65) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL898965 | 0.77 | CA12 (0.65) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL995945 | 0.74 | CA12 (0.62) | CA12CA7CA14SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 804 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192833-B1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2026-01-21 | — | — | EP | claimed |
| CN-118666780-A | Method for preparing morpholinosulfonamide compound by microwave promotion | 邵阳学院 | 2024-09-20 | — | — | CN | claimed |
| CN-117384673-A | Extraction process for producing heavy aromatic derivative | 宁波博汇化工科技股份有限公司 | 2024-01-12 | — | — | CN | claimed |
| EP-3860998-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO INC (US) | 2023-12-27 | — | — | EP | claimed |
| US-11471455-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | ANNAPURNA BIO, INC. (US) | 2022-10-18 | — | — | US | claimed |
| EP-2350068-B1 | UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2017-08-30 | — | — | EP | claimed |
| CN-103339132-B | Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredi | 株式会社麦迪帕克特 | 2017-02-15 | — | — | CN | claimed |
| EP-2863914-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-04-29 | — | — | EP | claimed |
| WO-2013192125-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-12-27 | — | — | WO | claimed |
| CN-103339132-A | Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredi | YOUAI CO LTD | 2013-10-02 | — | — | CN | claimed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| EP-0637965-B1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | claimed |
| US-20020128247-A1 | Beta3 agonists and uses thereof | DOW ROBERT L (US) | 2002-09-12 | — | — | US | claimed |
| EP-1236723-A1 | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | claimed |
| WO-2001040515-A1 | GAPPED OLIGOMERS HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| US-5843905-A | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-01 | — | — | US | claimed |
| EP-0644197-B1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | VERTEX PHARMA (US) | 1998-09-09 | — | — | EP | claimed |
| US-5677283-A | α-heteroaryloxymethyl ketones as interleukin - 1 β converting enzyme inhibitors | SANOFI (FR) | 1997-10-14 | — | — | US | claimed |
| EP-0644198-A1 | Alpha-heteroaryloxymethyl ketones as interleukin-1beta converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-03-22 | — | — | EP | claimed |
| EP-0644197-A1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-03-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128247-A1 | Beta3 agonists and uses thereof | ADRB3, ADRB1, ADRB2 | CA12 4686/4885CA7 4193/4885CA14 4779/4885 |
| US-11471455-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | APLNR, AGTR1, AGTR2 | CA12 2101/4885CA7 2242/4885CA14 3885/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | CA12 1870/4885CA7 1390/4885CA14 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.